TY - JOUR
T1 - FEasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld deviCES
T2 - Results of a pilot study
AU - Kaiser, Peter K.
AU - Wang, Yi Zhong
AU - He, Yu Guang
AU - Weisberger, Annemarie
AU - Wolf, Stephane
AU - Smith, Craig H.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - PURPOSE:: This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab. METHODS:: Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT. RESULTS:: Among 160 patients from 24 U.S. centers enrolled in the study (103 [64%] ≥75 years of age), 84.7% on average complied with daily mVT testing and ∼98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders. CONCLUSION:: Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.
AB - PURPOSE:: This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab. METHODS:: Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT. RESULTS:: Among 160 patients from 24 U.S. centers enrolled in the study (103 [64%] ≥75 years of age), 84.7% on average complied with daily mVT testing and ∼98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders. CONCLUSION:: Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.
KW - Health Management Tool
KW - age-related macular degeneration
KW - bestcorrected visual acuity
KW - central retinal subfield thickness
KW - choroidal neovascularization
KW - myVisionTrack
KW - ranibizumab
KW - remotemonitoring
KW - retinal disease
KW - shape discriminationhyperacuity
UR - http://www.scopus.com/inward/record.url?scp=84885022095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885022095&partnerID=8YFLogxK
U2 - 10.1097/IAE.0b013e3182899258
DO - 10.1097/IAE.0b013e3182899258
M3 - Article
C2 - 23609122
AN - SCOPUS:84885022095
SN - 0275-004X
VL - 33
SP - 1863
EP - 1870
JO - Retina
JF - Retina
IS - 9
ER -